Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816302 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TDP1POLBGAAL3MBTL1 | |
| SCHEMBL2820413 | 0.80 | CYP3A4 (0.44) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL395055 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL30279254 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL1684443 | 0.76 | POLB (0.42) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL2813687 | 0.74 | LOXL2 (0.48) | ALDH1A1POLBKAT2BGAAHTT | |
| SCHEMBL18053615 | 0.73 | POLB (0.47) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL2814724 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TDP1CYP3A4POLBGAA | |
| SCHEMBL2815063 | 0.73 | ALDH1A1 (0.45) | ALDH1A1TDP1CYP3A4POLBKAT2B | |
| SCHEMBL2013672 | 0.73 | GAA (0.43) | ALDH1A1TDP1CYP3A4POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | ALDH1A1 1769/4885TDP1 4258/4885CYP3A4 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.